Bitget App
Trade smarter
MarketsTradeFuturesEarnSquareMore
ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments

ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments

Bitget-RWA2025/11/17 20:40
By:Bitget-RWA

- Aligos Therapeutics (ALGS) saw a 12.49% 7-day stock decline despite positive HBV/MASH trial data. - Pevifoscorvir showed superior HBV DNA suppression and safety, with Phase II trials ongoing for 2026-2027 data. - ALG-009 demonstrated metabolic benefits for MASH, positioning Aligos as a key player in liver disease innovation. - Recent 23,600-share equity grants to new hires aim to strengthen R&D capabilities and operational growth.

As of November 17, 2025,

(ALGS) experienced a 5.16% decline over the past day, falling to $0.1512. Over the previous week, the token dropped 12.49%, with a 15.05% decrease in the past month and a 54.95% loss over the last year. Although the price has trended downward, recent advancements in the company’s drug development pipeline have brought into the spotlight within the biopharmaceutical industry.

Encouraging Clinical Results for HBV and MASH

ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments image 0
Therapeutics presented promising updates from its ongoing clinical studies at the Jefferies London Healthcare Conference on November 17, 2025. The company’s experimental treatment for chronic hepatitis B, Pevifoscorvir, outperformed standard therapies in reducing HBV DNA and lowering antigen levels. The therapy also showed no signs of resistance and maintained a strong safety record. A global Phase II study is in progress, with interim findings anticipated in 2026 and final results expected in 2027.

At the same time, Aligos shared advancements in its programs targeting MASH and obesity. ALG-009, another leading candidate, has demonstrated greater effectiveness and metabolic improvements, showing significant promise for treating metabolic dysfunction-associated steatohepatitis (MASH). These achievements indicate that the company is making substantial progress in addressing critical gaps in liver and viral disease treatments.

Focused R&D and Clinical Progress

Aligos bases its strategy on scientific innovation, building a pipeline aimed at challenging diseases such as HBV and MASH. During the recent conference, company leaders reiterated their dedication to creating top-tier therapies, highlighting their long-term goal of enhancing patient care through advanced medical solutions.

The company’s ongoing clinical work demonstrates its commitment to assembling a strong portfolio that targets persistent and widespread illnesses. With both Pevifoscorvir and ALG-009 actively being tested, Aligos is set to deliver important clinical data soon, which could impact investor confidence and the company’s market stance.

Stock Option Awards for Recent Employees

On November 14, 2025, Aligos revealed it had granted stock options under its 2024 Inducement Plan to new team members. These non-qualified options were provided to help attract and keep skilled professionals, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant covers 23,600 shares, with the exercise price matching the closing price on the grant date. Vesting will occur over four years, with 25% vesting each year and the remainder vesting monthly, contingent on continued employment.

This initiative highlights the company’s commitment to investing in its personnel, supporting its clinical ambitions, and enhancing operational strength. The equity awards are part of Aligos’ broader growth plan and its mission to bring innovative treatments to patients who need them most.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

ZKP's Build-First Movement: $100M Infrastructure Set, Speculation Not Permitted

- ZKP’s $100M pre-launch infrastructure includes $17M in Proof Pods hardware, enabling immediate global deployment post-presale. - The project’s real-time tracking dashboard links rewards to device performance and market prices, ensuring transparent, self-stabilizing economics. - Daily on-chain auctions distribute 200M tokens proportionally, eliminating gas wars and creating mathematically verifiable fairness for all participants. - Institutional interest grows as ZKP’s encrypted AI architecture attracts e

Bitget-RWA2025/11/18 00:50

Solana's Latest Price Swings and Network Stability: Should Investors See a Chance to Buy or a Reason for Caution?

- Solana (SOL) demonstrates 2025 network resilience with 16-month uptime, 200M+ daily transactions, and 1M+ TPS via Frankendancer upgrades. - Price volatility sees 48% pullback from $293 high to $153, driven by regulatory risks, macroeconomic shifts, and external shocks like Sharps Technology's treasury losses. - Institutional adoption (e.g., VanEck's $1B ETF) and 50% staking growth signal long-term potential, though daily 6% price swings highlight market sentiment risks. - Network stability remains intact

Bitget-RWA2025/11/18 00:50
Solana's Latest Price Swings and Network Stability: Should Investors See a Chance to Buy or a Reason for Caution?